MEK inhibitors are currently in clinical development for a variety of cancers, including lung cancer, with mutations specifically in the oncogene RAS or its downstream signalling components (for example, BRAF), which occur in a large number of cancers. Here, MAP2K7 is linked to lung carcinoma.